bioAffinity Technologies (NASDAQ:BIAF) versus Oscar Health (NYSE:OSCR) Head-To-Head Comparison

bioAffinity Technologies (NASDAQ:BIAF) and Oscar Health (NYSE:OSCR) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.

Earnings & Valuation

This table compares bioAffinity Technologies and Oscar Health”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioAffinity Technologies	$6.16 million	0.26	-$14.91 million	($44.27)	-0.06
Oscar Health	$17.47 billion	0.54	-$443.15 million	$2.42	12.70

bioAffinity Technologies has higher earnings, but lower revenue than Oscar Health. bioAffinity Technologies is trading at a lower price-to-earnings ratio than Oscar Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares bioAffinity Technologies and Oscar Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-278.90%	-278.67%	-154.52%
Oscar Health	4.90%	49.39%	9.29%

Institutional and Insider Ownership

1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 75.7% of Oscar Health shares are held by institutional investors. 2.4% of bioAffinity Technologies shares are held by insiders. Comparatively, 22.6% of Oscar Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for bioAffinity Technologies and Oscar Health, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	1	0	0	0	1.00
Oscar Health	1	7	4	1	2.38

Oscar Health has a consensus target price of $34.60, indicating a potential upside of 12.55%. Given Oscar Health’s stronger consensus rating and higher possible upside, analysts clearly believe Oscar Health is more favorable than bioAffinity Technologies.

Volatility & Risk

bioAffinity Technologies has a beta of -1.03, indicating that its stock price is 203% less volatile than the S&P 500. Comparatively, Oscar Health has a beta of 2.56, indicating that its stock price is 156% more volatile than the S&P 500.

Summary

Oscar Health beats bioAffinity Technologies on 14 of the 15 factors compared between the two stocks.

About bioAffinity Technologies

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

About Oscar Health

Oscar Health, Inc. operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was incorporated in 2012 and is headquartered in New York, New York.